The DOI matches its Crossref record; the references it cites are not checked yet.
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
Open accessAbstract
Hypoxia inducible factor (HIFs) signaling contributes to malignant cell behavior in glioblastoma (GBM). We investigated a novel HIF2α inhibitor, PT2385, both in vitro, with low-passage patient-derived cell lines, and in vivo, using orthotopic models of glioblastoma. We focused on analysis of HIF2α expression in situ, cell survival/proliferation, and survival in brain tumor-bearing mice treated with PT2385 alone and in combination with standard of care chemoradiotherapy. HIF2α expression increased with glioma grade, with over half of GBM specimens HIF2α positive. Staining clustered in perivascular and perinecrotic tumor regions. Cellular phenotype including proliferation, viability, migration/invasion, and also gene expression were not altered after PT2385 treatment. In the animal model, PT2385 single-agent treatment did improve median overall survival compared to placebo (p = 0.04, n = 21) without a bioluminescence correlate (t = 0.67, p = 0.52). No difference in animal survival was seen in combination treatment with radiation (RT)/temozolomide (TMZ)/PT2385 (p = 0.44, n = 10) or mean tumor bioluminescence (t 1.13, p = 0.32). We conclude that HIF2α is a reasonable novel therapeutic target as expressed in the majority of glioblastomas in our cohort. PT2385 as a single-agent was efficacious in vivo, however, an increase in animal survival was not seen with PT2385 in combination with RT/TMZ. Further study for targeting HIF2α as a therapeutic approach in GBM is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Intriguingly, cleavage of CD44 in GBM stem-like cells releases an intracellular domain (CD44ID) that binds to HIF-2α, but not HIF-1α, and protects it from degradation in the presence of oxygen. This enhances HIF-2α transcriptional activity in a CBP/p300 dependent manner [53].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 43 · Cited by 45
Metadata
- Authors
- Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., Frenkel, M. B., Hawkins, G. A., Herpai, D., Sanders, S., Sarkaria, J. N., Lesser, G. J., Debinski, W., & Strowd, R. E.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- Mayo Clinic (US)
- Corresponding author
- Renfrow, Jaclyn J.
- ORCID
- Venue
- Scientific Reports
- Published
- 2020-09-16
- Volume
- 10
- Issue
- 1
- Pages
- 15195-15195
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7495485
- OpenAlex
- W3087039777
- Cited by
- 45
- References
- 43
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 16
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Musella Foundation For Brain Tumor Research and Information
- Conquer Cancer Foundation (P30CA012197)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA012197-39)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- glioblastoma, HIF-2α, PT2385, tumor hypoxia, chemoradiotherapy, temozolomide, radiotherapy, patient-derived cell lines, orthotopic mouse model, overall survival, therapeutic target
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Brain Neoplasms, Cell Movement, Glioblastoma, Humans, Indans, Mice, Nude, Sulfones, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Molecular Targeted Therapy, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. https://app.cochat.ai/papers/10.1038/s41598-020-72290-2
- The paper
- Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., Frenkel, M. B., Hawkins, G. A., Herpai, D., Sanders, S., Sarkaria, J. N., Lesser, G. J., Debinski, W., & Strowd, R. E. (2020). Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Scientific Reports. https://doi.org/10.1038/s41598-020-72290-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.